ArticleVeterinary sciences2025
Pilot Study of a Novel First-Line Protocol (THOP) for Intermediate-Large B-Cell Lymphoma in Dogs.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The current standard of care for treatment of intermediate-large B-cell lymphoma in dogs is a CHOP-based chemotherapy protocol. On-protocol disease progression is reported to be temporally associated with cyclophosphamide administration. The objectives of this prospective pilot clinical trial were to describe the adverse event profile and identify early signal of efficacy of a novel cyclophosphamide-free chemotherapy protocol consisting of temozolomide, doxorubicin, vincristine, and prednisone (THOP) as first-line treatment in dogs with diffuse large cell B-cell lymphoma. Treatment-naïve dogs with intermediate-large B-cell lymphoma were enrolled. THOP was administered as a three-week cycle for five cycles. Fourteen dogs were enrolled. All dogs achieved complete remission with a median time to progression (TTP) of 269 days and a median survival of 433 days. There were five grade III and four grade IV hematologic toxicities reported; one grade III gastrointestinal toxicity was observed. THOP appears to be well tolerated and an effective first-line protocol for the treatment of intermediate-large B-cell lymphoma in dogs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.